RegeneRx Announces Final Clinical Results from Phase | Trial with RGN-352
RegeneRx Announces Final Clinical Results from Phase | Trial with RGN-352
REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate [...]